WCA recommendations for the long-term treatment of panic disorder. 2003

Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
Division of Psychiatry, Huddinge University Hospital, Stockholm, Sweden. mpollack@partners.org

What are the symptoms of panic disorder and how is the disorder most effectively treated? One of the most commonly encountered anxiety disorders in the primary care setting, panic disorder is a chronic and debilitating illness. The core symptoms are recurrent panic attacks coupled with anticipatory anxiety and phobic avoidance, which together impair the patient's professional, social, and familial functioning. Patients with panic disorder have medically unexplained symptoms that lead to overutilization of healthcare services. Panic disorder is often comorbid with agoraphobia and major depression, and patients may be at increased risk of cardiovascular disease and, possibly, suicide. Research into the optimal treatment of this disorder has been undertaken in the past 2 decades, and numerous randomized, controlled trials have been published. Selective serotonin reuptake inhibitors have emerged as the most favorable treatment, as they have a beneficial side-effect profile, are relatively safe (even if taken in overdose), and do not produce physical dependency. High-potency benzodiazepines, reversible monoamine oxidase inhibitors, and tricyclic antidepressants have also shown antipanic efficacy. In addition, cognitive-behavioral therapy has demonstrated efficacy in the acute and long-term treatment of panic disorder. An integrated treatment approach that combines pharmacotherapy with cognitive-behavioral therapy may provide the best treatment. Long-term efficacy and ease of use are important considerations in treatment selection, as maintenance treatment is recommended for at least 12-24 months, and in some cases, indefinitely.

UI MeSH Term Description Entries
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000929 Antidepressive Agents, Tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. Antidepressants, Tricyclic,Tricyclic Antidepressant,Tricyclic Antidepressant Drug,Tricyclic Antidepressive Agent,Tricyclic Antidepressive Agents,Antidepressant Drugs, Tricyclic,Agent, Tricyclic Antidepressive,Agents, Tricyclic Antidepressive,Antidepressant Drug, Tricyclic,Antidepressant, Tricyclic,Antidepressive Agent, Tricyclic,Drug, Tricyclic Antidepressant,Drugs, Tricyclic Antidepressant,Tricyclic Antidepressant Drugs,Tricyclic Antidepressants
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D015928 Cognitive Behavioral Therapy A directive form of psychotherapy based on the interpretation of situations (cognitive structure of experiences) that determine how an individual feels and behaves. It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and verbal techniques to identify and correct negative thinking that is at the root of the aberrant behavior. Behavior Therapy, Cognitive,Cognitive Behaviour Therapy,Cognitive Therapy,Psychotherapy, Cognitive,Cognition Therapy,Cognitive Behavior Therapy,Cognitive Psychotherapy,Therapy, Cognition,Therapy, Cognitive,Therapy, Cognitive Behavior,Behavior Therapies, Cognitive,Behavioral Therapies, Cognitive,Behavioral Therapy, Cognitive,Behaviour Therapies, Cognitive,Behaviour Therapy, Cognitive,Cognition Therapies,Cognitive Behavior Therapies,Cognitive Behavioral Therapies,Cognitive Behaviour Therapies,Cognitive Psychotherapies,Cognitive Therapies,Psychotherapies, Cognitive,Therapies, Cognition,Therapies, Cognitive,Therapies, Cognitive Behavior,Therapies, Cognitive Behavioral,Therapies, Cognitive Behaviour,Therapy, Cognitive Behavioral,Therapy, Cognitive Behaviour
D016584 Panic Disorder A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait. Panic Attacks,Attack, Panic,Attacks, Panic,Disorder, Panic,Disorders, Panic,Panic Attack,Panic Disorders
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin

Related Publications

Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
August 2003, CNS spectrums,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
August 2003, CNS spectrums,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
August 2003, CNS spectrums,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
February 1991, The Journal of clinical psychiatry,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
January 1998, The Journal of clinical psychiatry,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
February 1991, The Journal of clinical psychiatry,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
January 1993, Journal of psychiatric research,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
December 1998, Journal of clinical psychopharmacology,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
November 1990, The Journal of clinical psychiatry,
Mark H Pollack, and Christer Allgulander, and Borwin Bandelow, and Giovanni B Cassano, and John H Greist, and Eric Hollander, and David J Nutt, and Ahmed Okasha, and Richard P Swinson, and
January 1996, The Journal of clinical psychiatry,
Copied contents to your clipboard!